MCID: HNS001
MIFTS: 32

Hansen's Disease

Categories: Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hansen's Disease

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 53 3
Leprosy 53 73

Classifications:



External Ids:

UMLS 73 C0023343

Summaries for Hansen's Disease

NIH Rare Diseases : 53 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes. After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 3 and lepromatous leprosy. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Clofazimine and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Wikipedia : 76 Leprosy, also known as Hansen''s disease (HD), is a long-term infection by the bacterium Mycobacterium... more...

Related Diseases for Hansen's Disease

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 12.8
2 lepromatous leprosy 12.7
3 tuberculoid leprosy 12.6
4 borderline leprosy 12.6
5 leprosy 1 12.6
6 indeterminate leprosy 12.5
7 leprosy 5 12.3
8 leprosy 2 12.3
9 leprosy 4 12.3
10 leprosy 6 12.2
11 peripheral nervous system disease 11.3
12 sensory peripheral neuropathy 11.3
13 mononeuritis multiplex 11.3
14 buruli ulcer 11.3
15 mononeuropathy 11.3
16 chronic rhinitis 11.3
17 fetal thalidomide syndrome 11.3
18 trigeminal trophic syndrome 11.3
19 macs syndrome 11.0
20 autoimmune peripheral neuropathy 11.0
21 mycobacterium kansasii 11.0
22 neuropathy 10.4
23 leishmaniasis 10.3
24 lagophthalmos 10.3
25 foot drop 10.2
26 neuritis 10.2
27 australia antigen 10.2
28 hepatitis 10.1
29 amyloidosis 10.1
30 arthritis 10.1
31 cutaneous leishmaniasis 10.1
32 syphilis 10.1
33 malaria 10.0
34 glomerulonephritis 10.0
35 myiasis 10.0
36 tetanus 10.0
37 pulmonary tuberculosis 10.0
38 lupus erythematosus 10.0
39 molluscum contagiosum 10.0
40 systemic lupus erythematosus 10.0
41 lymphoma 10.0
42 psoriasis 10.0
43 thrombosis 10.0
44 elephantiasis 10.0
45 dysautonomia 10.0
46 hepatitis b 9.9
47 yaws 9.9
48 skin sarcoidosis 9.9
49 chromoblastomycosis 9.9
50 scabies 9.9

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease

Symptoms & Phenotypes for Hansen's Disease

Drugs & Therapeutics for Hansen's Disease

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clofazimine Approved, Investigational Phase 4,Phase 1,Phase 2 2030-63-9 2794
2
leucovorin Approved Phase 4,Phase 1,Phase 2 58-05-9 6006 143
3
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
4
Dapsone Approved, Investigational Phase 4,Phase 1,Phase 2 80-08-0 2955
5
Isoniazid Approved, Investigational Phase 4,Phase 1 54-85-3 3767
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Vitamins Phase 4
10 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 2,Phase 3,Phase 1
12 Folic Acid Antagonists Phase 4,Phase 1,Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
15 Vitamin B Complex Phase 4,Phase 1,Phase 2
16 Antimalarials Phase 4,Phase 1,Phase 2
17 Folate Phase 4,Phase 1,Phase 2
18 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
19 Vitamin B9 Phase 4,Phase 1,Phase 2
20 Antitubercular Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
22 Antimetabolites Phase 4,Phase 1
23 Lipid Regulating Agents Phase 4,Phase 1
24 Hypolipidemic Agents Phase 4,Phase 1
25 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
28
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
30
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
31
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
32
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 22916-47-8 4189
33
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
34
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
35
Goserelin Approved Phase 3 65807-02-5 47725 5311128
36
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
37
Benzoyl peroxide Approved Phase 3 94-36-0 7187
38
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
39
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 1 57-92-1 19649
40
Perphenazine Approved Phase 3 58-39-9 4748
41
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
42
Amitriptyline Approved Phase 3 50-48-6 2160
43
Infliximab Approved Phase 3 170277-31-3
44
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
45
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
46
Meglumine antimoniate Experimental, Investigational Phase 3,Early Phase 1 133-51-7
47 Hormones Phase 2, Phase 3,Phase 3,Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Not Applicable
49 Hormone Antagonists Phase 2, Phase 3,Not Applicable
50 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
2 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
3 Effect of Weight and/or Obesity on Dapsone Drug Concentrations Completed NCT01165840 Phase 4 Dapsone
4 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
5 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
6 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
7 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 Ciclosporin in the Management of New Type 1 Reactions in Leprosy Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
9 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
10 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
11 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
12 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
13 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
15 To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel Completed NCT02005666 Phase 3 Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;DUAC® Gel;Placebo
16 Treatment of Neuropathic Pain in Leprosy Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
17 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
19 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Not yet recruiting NCT03662022 Phase 3 Rifampicin
20 Leprosy Skin Test Antigens Trial Completed NCT00128193 Phase 2
21 Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy Completed NCT00919451 Phase 2 ciclosporin
22 Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum Completed NCT00919776 Phase 2 prednisolone;ciclosporin
23 Ciclosporin in the Management of New Erythema Nodosum Leprosum Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
24 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
25 Progression of HIV-Disease Under Low Dose Corticosteroids Completed NCT01299948 Phase 2 Prednisolone
26 A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
27 CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
28 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
29 Virgin Coconut Oil Oral Supplementation for Leprosy Patients Withdrawn NCT01885611 Phase 1, Phase 2
30 Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Completed NCT01006759 Phase 1
31 Leprosy Skin Test Antigens Phase 1 Completed NCT01920750 Phase 1
32 Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine Completed NCT00654316 Phase 1
33 Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
34 Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers Active, not recruiting NCT03302897 Phase 1
35 Montelukast in ENL Reaction Unknown status NCT00406861 Not Applicable montelukast in treatment of ENL reaction
36 Microcirculatory Impairment in Patients With Leprosy Completed NCT02085317 Not Applicable acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
37 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
38 The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients Completed NCT00860717 Not Applicable
39 Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses Completed NCT00138437
40 Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial Completed NCT02484469 Not Applicable
41 SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting Completed NCT02701439
42 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
43 γ-irradiated BCG to Train Innate Immunity Completed NCT02259608 Not Applicable
44 Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy Completed NCT00720980
45 Platelet Rich Plasma and Perineural Injection Therapy for Carpal Tunnel Syndrome Completed NCT02696161 Not Applicable
46 Genetics of Hepatitis C Virus Infection Completed NCT00005657
47 Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis Completed NCT00772408
48 Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Completed NCT01050777 Early Phase 1 Liposomal meglumine antimoniate (Glucantime);Liposomal meglumine antimoniate;Liposomal Paromomycin;Placebo
49 Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings Completed NCT03135366 Not Applicable
50 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Recruiting NCT03072004 Not Applicable

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Hansen's Disease

Anatomical Context for Hansen's Disease

MalaCards organs/tissues related to Hansen's Disease:

41
Skin, Eye, Testes, T Cells, Bone, Heart, Cortex

Publications for Hansen's Disease

Articles related to Hansen's Disease:

(show top 50) (show all 1117)
# Title Authors Year
1
Wide Awake Tendon Transfers in Leprosy Patients in India. ( 30470333 )
2019
2
Factors associated with the development of physical disabilities in Hansen's disease. ( 29972464 )
2018
3
Multiple cranial nerve palsies secondary to a recurrence of Hansen's disease. ( 29330278 )
2018
4
Acute scrotum: Hansen's disease versus filariasis. ( 29900901 )
2018
5
Swollen hand joints, arthralgia, photosensitivity and generalized acquired cutis laxa-like presentation of leprosy. ( 30117713 )
2018
6
Chronic, persistent angioedema and sinusitis-like presentation of multibacillary leprosy. ( 29512945 )
2018
7
Mid borderline leprosy in type Bα Blaschko linear pattern: a rare phenomenon. ( 30345504 )
2018
8
Diffuse Cutaneous Leishmaniasis in an Immunocompromised Patient Resembling Histoid Hansen's Disease. ( 30505791 )
2018
9
Leprosy and American cutaneous leishmaniasis coinfection. ( 29641713 )
2018
10
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release. ( 30292246 )
2018
11
Acute renal failure by rapidly progressive glomerulonephritis with IgA deposition in a patient concomitantly diagnosed with multibacillary Hansen's disease: a case report. ( 30160772 )
2018
12
Guillain-Barre Syndrome: A Rare Presentation of Borderline Tuberculoid Leprosy with Type 1 Lepra Reaction. ( 30069105 )
2018
13
Relationship between bacilloscopy and operational classification of Hansen's disease in patients with reactions. ( 29924247 )
2018
14
[A case series of pure neural leprosy in patients diagnosed in a specialized center for the control of Hansen's disease in Colombia]. ( 30184345 )
2018
15
Target Hansen's disease. ( 30234065 )
2018
16
Practices for self-care in Hansen's disease: face, hands and feet. ( 30365764 )
2018
17
Barriers to Promoting Advance Care Planning for Residents Living in a Sanatorium for Hansen's Disease: A Qualitative Study of Residents and Staff in Japan. ( 30464777 )
2018
18
Genomic Reduction at TTC Repeats in the Bacterial Genome of Treated Cases of Hansen's Disease: A Possible Survival Mechanism of Mycobacterium leprae. ( 30504970 )
2018
19
Clinico-Histological Correlation in Hansen's Disease: Three-year Experience at a Newly Established Tertiary Care Center in Central India. ( 30504973 )
2018
20
Occult Hepatitis B Virus Infection in Patients with Leprosy. ( 30512182 )
2018
21
Borderline Lepromatous Leprosy: Uncommon Clinical Presentation. ( 30211733 )
2018
22
Extensive Lepromatous Lymphadenitis Preceding Lesions on the Face and Earlobes: An Unusual Presentation of Leprosy in Singapore. ( 29606944 )
2018
23
Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience. ( 29723371 )
2018
24
Leprosy Neuritis. ( 29789111 )
2018
25
Borderline tuberculoid leprosy mimicking sarcoidosis: A case report. ( 30095620 )
2018
26
Second-harmonic generation imaging analysis can help distinguish sarcoidosis from tuberculoid leprosy. ( 30516038 )
2018
27
Clinical management of leprosy patients during the yellow fever outbreak in Brazil. ( 30500328 )
2018
28
Assistive technologies for improving the oral hygiene of leprosy patients residing in a former leprosy colony in Betim, Minas Gerais, Brazil. ( 30044849 )
2018
29
Characterization of New Leprosy Cases in Northeast of Iran within the Last 15 Years. ( 30046211 )
2018
30
Tuberculosis and Leprosy Coinfection: A Perspective on Diagnosis and Treatment. ( 30046638 )
2018
31
Monitoring and detection of leprosy patients in Southwest China: A retrospective study, 2010-2014. ( 30061618 )
2018
32
Mandating nerve biopsy: A step towards personalizing therapy in pure neuritic leprosy. ( 30070007 )
2018
33
Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at the End of 6 Months: A Prospective Observational Study from Eastern India - a comment. ( 30078885 )
2018
34
Genetic Susceptibility to Leprosy-From Classic Immune-Related Candidate Genes to Hypothesis-Free, Whole Genome Approaches. ( 30079069 )
2018
35
New therapeutic patents used for the treatment of leprosy: a review. ( 30081970 )
2018
36
Interleukin-10 Producing Regulatory B Cells Transformed CD4+CD25- Into Tregs and Enhanced Regulatory T Cells Function in Human Leprosy. ( 30083152 )
2018
37
Mikomeseng: Leprosy, Legitimacy and Francoist Repression in Spanish Guinea. ( 30089939 )
2018
38
Complement receptor 1 (CR1, CD35) association with susceptibility to leprosy. ( 30092084 )
2018
39
Langerin (CD207)-positive cells in leprosy: Possible implications for pathogenesis of the disease with special emphasis on dermal immunoreactivity. ( 30118799 )
2018
40
Epidemiological and geographical characterization of leprosy in a Brazilian hyperendemic municipality. ( 30133668 )
2018
41
Anti-leprosy drug Clofazimine binds to human Raf1 kinase inhibitory protein and enhances ERK phosphorylation. ( 30137201 )
2018
42
Whole blood profiling of leprosy type 1(reversal) reactions highlights prominence of innate immune response genes. ( 30143000 )
2018
43
Experts fear a resurgence of leprosy in India. ( 30152333 )
2018
44
Leprosy in individuals under the age of fifteen in priority cities, Mato Grosso, Brazil. ( 30156663 )
2018
45
IgM Anti PGL-1 Antibody Level in Patients with Leprosy: A Comparative Study between Ear Lobes Capillary and Median Cubital Vein Blood Samples. ( 30159054 )
2018
46
Lessons From Leprosy: Peripheral Neuropathies and Deformities in Chronic Demyelinating Diseases. ( 30177357 )
2018
47
Evaluation of Auramine O staining and conventional PCR for leprosy diagnosis: A comparative cross-sectional study from Ethiopia. ( 30180155 )
2018
48
A 13-Year-Old with Coexistence of Gastric Volvulus and Leprosy: A Case Report of Two Rare Entities. ( 30186647 )
2018
49
Worsening of the disability grade during leprosy treatment: prevalence and its determinants in Southern Nigeria. ( 30189090 )
2018
50
Phenotypic and functional features of innate and adaptive immunity as putative biomarkers for clinical status and leprosy reactions. ( 30195647 )
2018

Variations for Hansen's Disease

Expression for Hansen's Disease

Search GEO for disease gene expression data for Hansen's Disease.

Pathways for Hansen's Disease

GO Terms for Hansen's Disease

Sources for Hansen's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....